Vaccitech Announces Pricing of Initial Public Offering
April 29 2021 - 6:49PM
Vaccitech plc (“Vaccitech”) (Nasdaq: VACC), a clinical-stage
biopharmaceutical company engaged in the discovery and development
of novel immunotherapeutics and vaccines for the treatment and
prevention of infectious diseases and cancer, today announced the
pricing of its initial public offering in the United States of
6,500,000 American Depositary Shares (“ADSs”) representing
6,500,000 ordinary shares at an initial public offering price of
$17.00 per ADS for total gross proceeds of $110.5 million. All ADSs
sold in the offering are being offered by Vaccitech. The ADSs are
expected to begin trading on The Nasdaq Global Market on April 30,
2021 under the ticker symbol “VACC.” In addition, Vaccitech
has granted the underwriters a 30-day option to purchase up to an
additional 975,000 ADSs at the initial public offering price, less
underwriting discounts and commissions. The offering is expected to
close on May 4, 2021, subject to satisfaction of customary closing
conditions.
Morgan Stanley, Jefferies, Barclays and William
Blair are acting as book-runners for the offering. H.C. Wainwright
& Co. is acting as lead manager for the offering.
A registration statement on Form S-1 relating to
these securities was declared effective on April 29, 2021. The
securities referred to in this announcement are being offered only
by means of a prospectus. A copy of the final prospectus, when
available, may be obtained from: Morgan Stanley & Co. LLC,
Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New
York, NY 10014, or by email at prospectus@morganstanley.com;
Jefferies LLC, Attention: Equity Syndicate Prospectus Department,
520 Madison Avenue, 2nd Floor, New York, NY 10022, by
telephone at (877) 821-7388 or by email
at prospectus_department@jefferies.com; Barclays Capital Inc.,
c/o Broadridge Financial Solutions, 1155 Long Island Avenue,
Edgewood, NY 11717 or by email
at barclaysprospectus@broadridge.com or telephone at
1-888-603-5847; or William Blair & Company, L.L.C., Attention:
Prospectus Department, 150 North Riverside Plaza, Chicago, IL
60606, by telephone at (800) 621-0687, or by email at
prospectus@williamblair.com.
This press release shall not constitute an offer
to sell or the solicitation of an offer to buy these securities,
nor shall there be any sale of any securities in any state or
jurisdiction in which such offer, solicitation, or sale would be
unlawful prior to registration or qualification under the
securities laws of any such state or jurisdiction.
About Vaccitech plcVaccitech is
a clinical-stage biopharmaceutical company engaged in the discovery
and development of novel immunotherapeutics and vaccines for the
treatment and prevention of infectious diseases and cancer. The
company’s proprietary platform comprises proprietary modified
simian adenoviral vectors, known as ChAdOx1 and ChAdOx2, as well as
the well-validated Modified Vaccinia Ankara, or MVA, boost vector,
both with demonstrable safety profiles and without the ability to
replicate in humans. The combination of a ChAdOx prime treatment
with subsequent MVA boost has consistently generated significantly
higher magnitudes of CD8+ T cells compared with other technologies
and approaches. The company has a broad pipeline of both clinical
and preclinical stage therapeutic programs in solid tumors and
viral infections and prophylactic viral vaccine programs. Vaccitech
co-invented a COVID-19 vaccine with the University of Oxford, now
approved for use in many territories and exclusively licensed
worldwide to AstraZeneca through Oxford University Innovation, or
OUI. Vaccitech is entitled to receive a share of the milestones and
royalty income received by OUI from AstraZeneca.
Vaccitech Media contacts:Katja Stout, Scius
Communications (EU)Direct: +44 (0)
7789435990Email: katja@sciuscommunications.com
Ryo Imai / Robert Flamm, Ph.D. (US), Burns McClellan,
Inc.212-213-0006 ext. 315 / 364Email:
rimai@burnsmc.com / rflamm@burnsmc.com
Henry Hodge, VaccitechDirect: +44 (0) 7533 421
442Email: henry.hodge@vaccitech.co.uk
Vaccitech (NASDAQ:VACC)
Historical Stock Chart
From Aug 2024 to Sep 2024
Vaccitech (NASDAQ:VACC)
Historical Stock Chart
From Sep 2023 to Sep 2024